Hermelin v. K-V Pharmaceutical Co.

54 A.3d 1093, 2012 WL 395826, 2012 Del. Ch. LEXIS 23
CourtCourt of Chancery of Delaware
DecidedFebruary 7, 2012
DocketCivil Action No. 6936-VCG
StatusPublished
Cited by14 cases

This text of 54 A.3d 1093 (Hermelin v. K-V Pharmaceutical Co.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hermelin v. K-V Pharmaceutical Co., 54 A.3d 1093, 2012 WL 395826, 2012 Del. Ch. LEXIS 23 (Del. Ct. App. 2012).

Opinion

OPINION

GLASSCOCK, Vice Chancellor.

No corporation can be a success unless led by competent and energetic officers and directors. Such individuals would be unwilling to serve if exposed to the broad range of potential liability and legal costs inherent in such service despite the most scrupulous regard for the interests of stockholders. This is the rationale behind the indemnification and advancement provisions of Delaware corporate law. Currently before me are several issues arising from those provisions and from a contract between the parties providing for the indemnification of the Plaintiff.

Delaware statutory law is largely enabling with respect to the indemnification rights of corporate officers and directors. The Delaware General Corporation Law (“DGCL”) sets two boundaries for indemnification: The statute requires a corporation to indemnify a person who was made a party to a proceeding by reason of his service to the corporation and has achieved success on the merits or otherwise in that proceeding. At the other end of the spectrum, the statute prohibits a corporation from indemnifying a corporate official who was not successful in the underlying proceeding and has acted, essentially, in bad faith. In setting these broad boundaries, Delaware law furthers important public policy goals of encouraging corporate officials to resist unmeritorious claims and allowing corporations to attract qualified officers and directors by agreeing to indemnify them against losses and expenses they incur personally as a result of their [1095]*1095service.1 Prohibiting the indemnification of unsuccessful “bad actors” also relieves stockholders of the costs of faithless behavior and provides corporate officials with an appropriate incentive to avoid such acts to begin with.

For any circumstance between the extremes of “success” and “bad faith,” the DGCL leaves the corporation with the discretion to determine whether to indemnify its officer or director. Consequently, corporations routinely refine their indemnification obligations by charter, bylaw, or contract. Thus, because indemnification between the boundaries of “success” and “bad faith” is permissive, when a corporation has established by contract the indemnification rights of a corporate official, the agreement controls unless it conflicts with a mandatory statutory provision.

In this case, the Plaintiff, a former corporate officer, is suing the Defendant, his former employer, for advancement and indemnification in connection with several proceedings that arose out of regulatory and criminal investigations at the Defendant corporation. The Plaintiff and Defendant are parties to an Indemnification Agreement that generally makes mandatory what are permissive provisions for indemnification under the DGCL. The dispute centers around whether the Plaintiff succeeded on the merits of any of the aforementioned proceedings, thus entitling him to indemnification as a matter of law, or whether additional discovery is required to determine whether the Plaintiff acted in good faith, in which case he will be entitled to indemnification under the Indemnification Agreement. The parties have briefed the matter, and I consider it submitted as on cross-motions for partial summary judgment. For the indemnification claims that require additional discovery regarding the Plaintiffs good faith, I set forth the scope of evidence relevant to that issue.2 Finally, I address the remaining advancement issue in the case.

I. FACTUAL BACKGROUND3

This case involves a number of indemnification and advancement claims by Plaintiff Marc S. Hermelin against his former employer, Defendant K-V Pharmaceutical Company (“KV”). Hermelin, who served as CEO of KV from 1975 to 2008 and held various positions on KVs Board of Directors from 1975 to 2010, seeks indemnification or advancement for several criminal, civil, and regulatory matters that arose following KVs distribution of oversized morphine sulfate tablets into the market. The facts giving rise to the proceedings at issue are more relevant to permissive indemnification than mandatory indemnification, the former of which requires that the indemnitee meet a “good faith” standard of conduct. Although, as I explain below, I cannot reach a decision on permissive indemnification on the current record, a brief summary of the undisputed background facts is useful.

In May 2008, two pharmacies notified KV that they had received oversized morphine sulfate tablets from KV. These tablets were manufactured by KV and distributed by ETHEX Corporation (“ETHEX”), a subsidiary of KV. KV began an internal investigation into the cause of the distribu[1096]*1096tion of the oversized tablets. In the course of its investigation, KV discovered that it had manufactured additional oversized tablets, including propafenone, an anti-arrhythmic drug, and dextroampheta-mine sulfate, a stimulant. KV notified the Food and Drug Administration (“FDA”) of its discovery of the oversized morphine sulfate tablets, but it did not report its discovery of the other oversized pills.

Following these events and after receiving complaints from employees, KV’s Audit Committee conducted an internal investigation and ultimately decided to terminate for cause Hermelin’s employment as CEO of KV. The disclosure of Hermelin’s termination in KVs Form 8-K filing precipitated an investigation by the U.S. Attorney’s Office for the Eastern District of Missouri (“USAO”) and regulatory actions by the FDA and the Office of Inspector General of the Department of Health and Human Services (“OIG”). Hermelin seeks advancement and indemnification for several proceedings arising out of these investigations and regulatory actions.

A. Indemnification Matters

In his Verified Amended Complaint (“Complaint”), Hermelin sought a declaration that he was entitled to indemnification for six completed proceedings arising from his conduct during his employment with KV. Two of those proceedings are no longer at issue,4 as the matters have concluded and the Defendant has agreed not to seek claw-back on the amounts already advanced.5 I summarize below the remaining four proceedings: the Audit Committee Matter, the Criminal Matter, the FDA Consent Decree Matter, and the HHS Exclusion Matter. In summarizing these proceedings, I focus on the charges Hermelin faced and the outcomes he achieved, as those are the principal facts upon which I evaluate whether Hermelin succeeded on the merits or otherwise.

Arguing that none of these matters justifies mandatory indemnification, KV invokes the “victory” of Pyrrhus of Epirus at the Battle of Asculum in 279 B.C. and asserts that any success by Hermelin in the underlying actions was a win as bad as a defeat.6 Pyrrhic victories, however, where success in the matter comes at great sacrifice, are entitled to mandatory indemnification under Delaware law.7 In any event, most of the “successes” alleged by Hermelin are not Pyrrhic wins at great cost, but instead losses akin to that of Lee at Appomattox, of which it may be said that the surrender on generous terms avoided an inevitable loss requiring supreme sacrifice, and was in that sense successful.

[1097]*10971. The Audit Committee Matter8

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Paul A. Rhodes, Ph.D. v. bioMérieux, Inc.
Court of Chancery of Delaware, 2024
Jmîchaele Keller v. Steep Hill, Inc.
Court of Chancery of Delaware, 2023
Mikhail Kokorich v. Momentus Inc.
Court of Chancery of Delaware, 2023
Shawn Evans v. Avande, Inc.
Court of Chancery of Delaware, 2022
Augustin Huret v. MondoBrain, Inc.
Court of Chancery of Delaware, 2022
Autumn Tangas v. IHOP
Sixth Circuit, 2019
Franklin Brown v. Rite Aid Corporation
Court of Chancery of Delaware, 2019
Sandt v. Energy Maintenance Services Group I, LLC
534 S.W.3d 626 (Court of Appeals of Texas, 2017)
Meyers v. Quiz-Dia LLC
Court of Chancery of Delaware, 2017
William Horne v. Optimiscorp
Court of Chancery of Delaware, 2017

Cite This Page — Counsel Stack

Bluebook (online)
54 A.3d 1093, 2012 WL 395826, 2012 Del. Ch. LEXIS 23, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hermelin-v-k-v-pharmaceutical-co-delch-2012.